COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY

摘要

Methods for treating a proliferative disease by administering a synergistic combination of an antibody against an epitope of CD33 (anti-CD33) and a combination of two or more individual chemotherapeutic agents is disclosed. The combination of chemotherapeutic agents may include cladribine, cytarabine, mitoxantrone, and filgrastim (CLAG-M), and the anti-CD33 may be a humanized monoclonal antibody against CD33 such as HuM195 conjugated with a radionuclide such as ¹³¹I or ²²⁵ Ac. The proliferative disease or disorder may be a hematological disease such as multiple myeloma, acute myeloid leukemia, and/or myelodysplastic syndrome. The method may be particularly useful for treatment of relapsed or refractory acute myeloid leukemia.